The joint venture which will focus on developing, manufacturing and promoting generic drugs, will be 51% owned by Fujifilm and 49% by the Indian drug maker.
The new company will use Fujifilm’s quality control technologies and Dr Reddy’s production technologies for active pharmaceutical ingredients and formulations.
Fujifilm president and CEO Shigetaka Komori said through Fujifilm’s material process technology and quality control system, they aim to contribute to the adoption of high quality and affordable generic drugs in Japanese market.